Login to Your Account



AAA Gets $57M for Pivotal Cancer Drug Trial, Acquisition

By Cormac Sheridan


Wednesday, July 27, 2011
Advanced Accelerator Applications SA (AAA) closed a €40 million (US$57.4 million) funding round that will enable the company to move its lead drug candidate Lutathera (lutate; 177Lutetium DOTA0-Tyr3-Octreotate) into pivotal trials in cancer later this year and to complete the acquisition of an as yet undisclosed firm that is developing a drug for ovarian cancer. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription